Search

Your search keyword '"Ueshima, Kazuomi"' showing total 562 results
Start Over Author "Ueshima, Kazuomi"
562 results on '"Ueshima, Kazuomi"'

1. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

Author

Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Vogel, Arndt, Tovoli, Francesco, Ueshima, Kazuomi, Aikata, Hiroshi, López, Carlos López, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel, Tamai, Toshiyuki, Saito, Kenichi, Dutcus, Corina E., and Lencioni, Riccardo

Published
2023
Full Text
View/download PDF

3. Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib.

Author

Kudo, Masatoshi, primary, Kato, Naoya, additional, Kondo, Shunsuke, additional, Inaba, Yoshitaka, additional, Ueshima, Kazuomi, additional, Sasaki, Mitsuhito, additional, Ogasawara, Sadahisa, additional, Sahara, Takatoshi, additional, Li, Shuyu D, additional, Shen, Jialing, additional, Kimura, Takayuki, additional, Dutta, Lea, additional, Tamai, Toshiyuki, additional, and Ikeda, Masafumi, additional

Published
2024
Full Text
View/download PDF

5. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.

Author

Aoki, Tomoko, Nishida, Naoshi, Kurebayashi, Yutaka, Sakai, Kazuko, Morita, Masahiro, Chishina, Hirokazu, Takita, Masahiro, Hagiwara, Satoru, Ida, Hiroshi, Ueshima, Kazuomi, Minami, Yasunori, Tsurusaki, Masakatsu, Nakai, Takuya, Sakamoto, Michiie, Nishio, Kazuto, and Kudo, Masatoshi

Subjects
WNT genes, CELL adhesion molecules, MYELOID-derived suppressor cells, REGULATORY T cells, TRANSCRIPTION factors, ADENOMATOUS polyposis coli, CD25 antigen, HEPATOCELLULAR carcinoma
Abstract

Introduction: Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype, their role on TME remains controversial. We aimed to clarify the heterogeneity of immunophenotype in HCC with Wnt/β-catenin mutations. Methods: This study includes 152 resected HCCs; mutations in the catenin beta-1, adenomatous polyposis coli, or AXIN1, or AXIN2 genes were defined as Wnt/β-catenin mutations. With hierarchical cluster analyses, TME was classified into inflamed or non-inflamed classes based on the gene expressions associated with T-cell activation. Expression profiles of molecules related to cell differentiation and biliary-stem cell markers were compared between the TME classes to investigate whether differences in tumor traits were associated with TME. Results: Forty of 152 (26.3%) HCCs carried the Wnt/β-catenin mutations. Of these, 33 were classified as non-inflamed (33/40, 82.5%) and 7 as inflamed (7/40, 17.5%). Non-inflamed class was characterized by low number of CD3+, CD4+, and CD8+ cells on immunostaining, and high mRNA expressions of AXIN2 and GLUL, which are involved in the canonical Wnt/β-catenin signaling and hepatocyte differentiation, respectively. Non-inflamed tumors showed higher enhancement on the hepatobiliary-phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) compared to inflamed tumors. HCCs classified as inflamed class are revealed to have high numbers of CD3+, CD4+, and CD8+ tumor infiltrating lymphocytes on immunostaining. This class is associated with increased expression of anti-epithelial cell adhesion molecule and FOXM1 accompanied by upregulation of genes related to interferon-gamma signaling, dendritic cell migration, regulatory T cells, and myeloid-derived suppressor cell activation and recognized as low enhancement nodule on Gd-EOB-DTPA-enhanced MRI. Conclusion: Heterogeneity of tumor traits and TME was observed in HCC with Wnt/β-catenin mutation. The potential was indicated that tumor traits and TME are determined not only by the activation of the HNF4A but also by FOXM1, both of which are downstream transcription factor of the Wnt/β-catenin signaling pathway. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Fontan術後に発症した切除不能肝細胞癌の1例

Author

Hagiwara, Satoru, primary, Ueshima, Kazuomi, additional, Nishida, Naoshi, additional, Ida, Hiroshi, additional, Minaga, Kosuke, additional, Minami, Yasunori, additional, Takita, Masahiro, additional, Aoki, Tomoko, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Matsubara, Takuya, additional, Omaru, Naoya, additional, Inamura, Noboru, additional, and Kudo, Masatoshi, additional

Published
2023
Full Text
View/download PDF

7. Two distinct characteristics of immune microenvironment in human hepatocellular carcinoma with Wnt/β-catenin mutations

Author

Aoki, Tomoko, primary, Nishida, Naoshi, additional, Kurebayashi, Yutaka, additional, Sakai, Kazuko, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Takita, Masahiro, additional, Hagiwara, Satoru, additional, Ida, Hiroshi, additional, Ueshima, Kazuomi, additional, Minami, Yasunori, additional, Tsurusaki, Masakatsu, additional, Nakai, Takuya, additional, Sakamoto, Michiie, additional, Nishio, Kazuto, additional, and Kudo, Masatoshi, additional

Published
2023
Full Text
View/download PDF

9. Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

Author

Hagiwara, Satoru, Watanabe, Tomohiro, Kudo, Masatoshi, Minaga, Kosuke, Komeda, Yoriaki, Kamata, Ken, Kimura, Masatomo, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Ueshima, Kazuomi, Minami, Yasunori, Aoki, Tomoko, Takita, Masahiro, Morita, Masahiro, Cishina, Hirokazu, Ida, Hiroshi, Park, Ah-Mee, and Nishida, Naoshi

Published
2021
Full Text
View/download PDF

10. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.

Author

Kudo, Masatoshi, Ueshima, Kazuomi, Saeki, Issei, Ishikawa, Toru, Inaba, Yoshitaka, Morimoto, Naoki, Aikata, Hiroshi, Tanabe, Nobukazu, Wada, Yoshiyuki, Kondo, Yasuteru, Tsuda, Masahiro, Nakao, Kazuhiko, Ito, Takanori, Hosaka, Tetsuya, Kawamura, Yusuke, Kuzuya, Teiji, Nojiri, Shunsuke, Ogawa, Chikara, Koga, Hironori, and Hino, Keisuke

Subjects
CHEMOEMBOLIZATION, HEPATOCELLULAR carcinoma, ABLATION techniques, PROGRESSION-free survival, OVERALL survival
Abstract

Introduction: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase 2, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better objective response rate (ORR) than sorafenib (jRCTs031180074). Methods: Participants were patients with HCC who had not previously received systemic therapy, hepatic arterial infusion chemotherapy, or immunotherapy and who were ineligible for resection or percutaneous ablation therapy. LEN was to be administered 14–21 days before the first TACE, stopped 2 days before TACE, and resumed 3 days after TACE. Key inclusion criteria were unresectable HCC, Child-Pugh A liver function, 0–2 prior TACE sessions, tumor size ≤10 cm, number of tumors ≤10, and ECOG performance status 0–1. Key exclusion criteria were vascular invasion and extrahepatic spread. The primary endpoint was progression-free survival (PFS) by RECICL, and secondary endpoints were time to untreatable progression, ORR, overall survival (OS), and safety. Results: A total of 62 HCC patients were enrolled in this trial. The median age was 72 years, 77.4% of patients were men, and 95.2% had PS 0. The primary endpoint of median PFS was 28.0 months (90% confidence interval [CI] 25.1–31.0) after a minimum 24 months of follow-up. The secondary endpoint of median OS was not reached (90% CI 35.5 months–NR). LEN-TACE achieved a high response rate and high complete response (CR) rate (4 weeks after the first TACE: ORR 79.0%, CR rate 53.2%; best response: ORR 88.7%, CR rate 67.7%) by RECICL. Exploratory subgroup analyses showed that the characteristics of responders/nonresponders (ORR and CR rate) were similar and that LEN-TACE would be effective in all subgroups, including the population in whom TACE alone would be less likely to be curative (e.g., patients with the non-simple nodular type or a high tumor burden). The relative dose intensity of LEN before the first TACE was important for achieving higher CR rate/ORR by LEN-TACE. No new safety concerns were observed. Conclusion: The results of this trial provide encouraging evidence, supporting the efficacy and favorable safety profile of LEN-TACE in patients who are ineligible for locoregional therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.

Author

Aoki, Tomoko, Kudo, Masatoshi, Ueshima, Kazuomi, Morita, Masahiro, Chishina, Hirokazu, Takita, Masahiro, Hagiwara, Satoru, Ida, Hiroshi, Minami, Yasunori, Tsurusaki, Masakatsu, and Nishida, Naoshi

Subjects
CELL death, REGULATORY T cells, VASCULAR endothelial growth factors, DISEASE progression, IMMUNE checkpoint inhibitors
Abstract

Introduction: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (HCC). While immune checkpoint inhibitor has revolutionized the concept of cancer treatment, it has also led to unexpected tumor growth. Regulatory T cells express PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptors, which are proliferated and activated by antibody binding, and their ratio to CD8+ T cells is altered, which is one of the causes for hyper progressive disease (HPD). We examined the frequency of HPD in anti-PD-1/PD-L1 monotherapy and combination therapy with vascular endothelial growth factor (VEGF) antibody and anti-CTLA-4 antibodies. Methods: This was a prospective and retrospective cohort study which enrolled 198 patients with unresectable HCC from January 2015 to December 2021 at the Kindai University Hospital. Fifty-eight patients received anti-PD-1/PD-L1 monotherapy, 119 patients combination with VEGF antibody, and 21 patients combination with anti-CTLA-4 antibody. We defined HPD as tumor growth rate (TGR) ratio ≥4, ΔTGR ≥40%, and tumor growth kinetics ratio ≥4. Results: The HPD rate was 10.3% (6/58) in anti-PD-1/PD-L1 monotherapy, 1.7% (2/119) in combination with VEGF antibody, and 4.8% (1/21) in combination with anti-CTLA-4 antibody (p = 0.034). The odds ratio for HPD in the combined anti-CTLA-4 antibody group was 0.433 (95% confidence interval [CI]: 0.05–3.83) when compared to the anti-PD-1/PD-L1 monotherapy group and 2.93 (95% CI: 0.25–33.79) when compared to the combined VEGF antibody group. Conclusion: The frequency of HPD in unresectable HCC compared to anti-PD-1/PD-L1 monotherapy was decreased with the combination with anti-VEGF antibody and not increased with anti-CTLA-4 antibody. Anti-PD-1/PD-L1 combined with anti-CTLA-4 antibody is now available in real-world and needs to be further validated with accumulated clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial

Author

Kamata, Ken, primary, Imai, Hajime, additional, Matsumoto, Hisakazu, additional, Yamashita, Yukitaka, additional, Kato, Takao, additional, Nishi, Katsuhisa, additional, Omoto, Shunsuke, additional, Minaga, Kosuke, additional, Yamao, Kentaro, additional, Hyodo, Tomoko, additional, Im, Sung‐Woon, additional, Hara, Akane, additional, Yoshikawa, Tomoe, additional, Ishikawa, Rei, additional, Okamoto, Ayana, additional, Yamazaki, Tomohiro, additional, Nakai, Atsushi, additional, Ueshima, Kazuomi, additional, Chiba, Yasutaka, additional, Takenaka, Mamoru, additional, Watanabe, Tomohiro, additional, Kitano, Masayuki, additional, and Kudo, Masatoshi, additional

Published
2023
Full Text
View/download PDF

13. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

Author

Kudo, Masatoshi, Ueshima, Kazuomi, Yokosuka, Osamu, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Akazawa, Kohei, Yoshimura, Ken-ichi, Johnson, Philip, and Arai, Yasuaki

Published
2018
Full Text
View/download PDF

14. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial

Author

Kudo, Masatoshi, primary, Ueshima, Kazuomi, additional, Saeki, Issei, additional, Ishikawa, Toru, additional, Inaba, Yoshitaka, additional, Morimoto, Naoki, additional, Aikata, Hiroshi, additional, Tanabe, Nobukazu, additional, Wada, Yoshiyuki, additional, Kondo, Yasuteru, additional, Tsuda, Masahiro, additional, Nakao, Kazuhiko, additional, Ito, Takanori, additional, Hosaka, Tetsuya, additional, Kawamura, Yusuke, additional, Kuzuya, Teiji, additional, Nojiri, Shunsuke, additional, Ogawa, Chikara, additional, Koga, Hironori, additional, Hino, Keisuke, additional, Ikeda, Masafumi, additional, Moriguchi, Michihisa, additional, Hisai, Takashi, additional, Yoshimura, Kenichi, additional, Furuse, Junji, additional, and Arai, Yasuaki, additional

Published
2023
Full Text
View/download PDF

15. Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma

Author

Aoki, Tomoko, primary, Kudo, Masatoshi, additional, Ueshima, Kazuomi, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Takita, Masahiro, additional, Hagiwara, Satoru, additional, Ida, Hiroshi, additional, Minami, Yasunori, additional, Tsurusaki, Masakatsu, additional, and Nishida, Naoshi, additional

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

Author

Kudo, Masatoshi, primary, Montal, Robert, primary, Finn, Richard S., primary, Castet, Florian, primary, Ueshima, Kazuomi, primary, Nishida, Naoshi, primary, Haber, Philipp K., primary, Hu, Youyou, primary, Chiba, Yasutaka, primary, Schwartz, Myron, primary, Meyer, Tim, primary, Lencioni, Riccardo, primary, and Llovet, Josep M., primary

Published
2023
Full Text
View/download PDF

20. Revisions of the clinical practice guidelines for hepatocellular carcinoma in 2021 version

Author

Takemura, Nobuyuki, primary, Tateishi, Ryosuke, additional, Yamashita, Tatsuya, additional, Watadani, Takeyuki, additional, Kaibori, Masaki, additional, Kubo, Shoji, additional, Shimada, Mitsuo, additional, Nagano, Hiroaki, additional, Hatano, Etsuro, additional, Aikata, Hiroshi, additional, Iijima, Hiroko, additional, Ueshima, Kazuomi, additional, Ohkawa, Kazuyoshi, additional, Genda, Takuya, additional, Tsuchiya, Kaoru, additional, Torimura, Takuji, additional, Ikeda, Masafumi, additional, Furuse, Junji, additional, Akahane, Masaaki, additional, Kobayashi, Satoshi, additional, Sakurai, Hideyuki, additional, Takeda, Atsuya, additional, Murakami, Takamichi, additional, Motosugi, Utaroh, additional, Matsuyama, Yutaka, additional, Kudo, Masatoshi, additional, and Hasegawa, Kiyoshi, additional

Published
2023
Full Text
View/download PDF

21. Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.

Author

Kudo, Masatoshi, primary, Aoki, Tomoko, additional, Ueshima, Kazuomi, additional, Tsuchiya, Kaoru, additional, Morita, Masahiro, additional, Hagiwara, Satoru, additional, Minami, Yasunori, additional, Ida, Hiroshi, additional, Nishida, Naoshi, additional, Ogawa, Chikara, additional, Tomonari, Tetsu, additional, Nakamura, Noriaki, additional, Kuroda, Hidekatsu, additional, Takebe, Atsushi, additional, Takeyama, Yoshifumi, additional, Hidaka, Masaaki, additional, Eguchi, Susumu, additional, Chan, Stephen Lam, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

22. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

Author

Kudo, Masatoshi, primary, Aoki, Tomoko, additional, Ueshima, Kazuomi, additional, Tsuchiya, Kaoru, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Takita, Masahiro, additional, Hagiwara, Satoru, additional, Minami, Yasunori, additional, Ida, Hiroshi, additional, Nishida, Naoshi, additional, Ogawa, Chikara, additional, Tomonari, Tetsu, additional, Nakamura, Noriaki, additional, Kuroda, Hidekatsu, additional, Takebe, Atsushi, additional, Takeyama, Yoshifumi, additional, Hidaka, Masaaki, additional, Eguchi, Susumu, additional, Chan, Stephen L, additional, Kurosaki, Masayuki, additional, and Izumi, Namiki, additional

Published
2023
Full Text
View/download PDF

24. Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi‐institutional propensity‐matched cohort study

Author

Komatsu, Shohei, primary, Ueshima, Kazuomi, additional, Kido, Masahiro, additional, Kuramitsu, Kaori, additional, Tsugawa, Daisuke, additional, Yanagimoto, Hiroaki, additional, Toyama, Hirochika, additional, Ku, Yonon, additional, Kudo, Masatoshi, additional, and Fukumoto, Takumi, additional

Published
2022
Full Text
View/download PDF

25. Progression from early to advanced stage of immune‐related cholangitis

Author

Hagiwara, Satoru, primary, Yoshida, Takeshi, additional, Nishida, Naoshi, additional, Ida, Hiroshi, additional, Ueshima, Kazuomi, additional, Minami, Yasunori, additional, Takita, Masahiro, additional, Aoki, Tomoko, additional, Morita, Masahiro, additional, Cishina, Hirokazu, additional, Komeda, Yoriaki, additional, Yoshida, Akihiro, additional, Hayashi, Hidetoshi, additional, Nakagawa, Kazuhiko, additional, and Kudo, Masatoshi, additional

Published
2022
Full Text
View/download PDF

26. Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus

Author

Iwamoto, Hideki, primary, Niizeki, Takashi, additional, Nagamatsu, Hiroaki, additional, Ueshima, Kazuomi, additional, Tani, Joji, additional, Kuzuya, Teiji, additional, Kasai, Kazuhiro, additional, Kooka, Yohei, additional, Hiraoka, Atushi, additional, Sugimoto, Rie, additional, Yonezawa, Takehiro, additional, Tanaka, Satoshi, additional, Deguchi, Akihiro, additional, Shimose, Shigeo, additional, Shirono, Tomotake, additional, Sakai, Miwa, additional, Suzuki, Hiroyuki, additional, Moriyama, Etsuko, additional, Koga, Hironori, additional, Torimura, Takuji, additional, and Kawaguchi, Takumi, additional

Published
2022
Full Text
View/download PDF

27. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines).

Author

Hasegawa, Kiyoshi, Takemura, Nobuyuki, Yamashita, Tatsuya, Watadani, Takeyuki, Kaibori, Masaki, Kubo, Shoji, Shimada, Mitsuo, Nagano, Hiroaki, Hatano, Etsuro, Aikata, Hiroshi, Iijima, Hiroko, Ueshima, Kazuomi, Ohkawa, Kazuyoshi, Genda, Takuya, Tsuchiya, Kaoru, Torimura, Takuji, Ikeda, Masafumi, Furuse, Junji, Akahane, Masaaki, and Kobayashi, Satoshi

Subjects
HEPATOCELLULAR carcinoma, HEPATOLOGY, EVIDENCE-based medicine, SYSTEMS development
Abstract

The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance–diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection

Author

Hagiwara, Satoru, primary, Nishida, Naoshi, additional, Ida, Hiroshi, additional, Ueshima, Kazuomi, additional, Minami, Yasunori, additional, Takita, Masahiro, additional, Aoki, Tomoko, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Komeda, Yoriaki, additional, Yoshida, Akihiro, additional, Hayashi, Hidetoshi, additional, Nakagawa, Kazuhiko, additional, and Kudo, Masatoshi, additional

Published
2022
Full Text
View/download PDF

30. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial

Author

Okita, Kiwamu, Izumi, Namiki, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi, Ikeda, Masafumi, Kokudo, Norihiro, Imanaka, Kazuho, Nishiguchi, Shuhei, Kondo, Shunsuke, Nishigaki, Yoichi, Shiomi, Susumu, Ueshima, Kazuomi, Isoda, Norio, Karino, Yoshiyasu, Kudo, Masatoshi, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Makuuchi, Masatoshi, Okusaka, Takuji, Hayashi, Norio, Ohashi, Yasuo, Kumada, Hiromitsu, and The Peretinoin Study Group

Published
2015
Full Text
View/download PDF

31. Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)

Author

Kudo, Masatoshi, primary, Ikeda, Masafumi, additional, Ueshima, Kazuomi, additional, Sakamoto, Michiie, additional, Shiina, Shuichiro, additional, Tateishi, Ryosuke, additional, Nouso, Kazuhiro, additional, Hasegawa, Kiyoshi, additional, Furuse, Junji, additional, Miyayama, Shiro, additional, Murakami, Takamichi, additional, Yamashita, Tatsuya, additional, and Kokudo, Norihiro, additional

Published
2022
Full Text
View/download PDF

32. Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.

Author

Ueshima, Kazuomi, primary, Ishikawa, Toru, additional, Saeki, Issei, additional, Morimoto, Naoki, additional, Aikata, Hiroshi, additional, Tanabe, Nobukazu, additional, Inaba, Yoshitaka, additional, Wada, Yoshiyuki, additional, Kondo, Yasuteru, additional, Tsuda, Masahiro, additional, Nakao, Kazuhiko, additional, Ikeda, Masafumi, additional, Moriguchi, Michihisa, additional, Ito, Takanori, additional, Kobayashi, Masahiro, additional, Koga, Hironori, additional, Hino, Keisuke, additional, Suzuki, Yoshiyuki, additional, Yoshimura, Kenichi, additional, and Kudo, Masatoshi, additional

Published
2022
Full Text
View/download PDF

33. Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

Author

Kudo, Masatoshi, primary, Ueshima, Kazuomi, additional, Nakahira, Shin, additional, Nishida, Naoshi, additional, Ida, Hiroshi, additional, Minami, Yasunori, additional, Nakai, Takuya, additional, Wada, Hiroshi, additional, Kubo, Shoji, additional, Ohkawa, Kazuyoshi, additional, Morishita, Asahiro, additional, Nomi, Takeo, additional, Ishida, Koji, additional, Kobayashi, Shogo, additional, Umeda, Makoto, additional, Tsurusaki, Masakatsu, additional, Chiba, Yasutaka, additional, Yoshimura, Kenichi, additional, Sakai, Kazuko, additional, and Nishio, Kazuto, additional

Published
2022
Full Text
View/download PDF

34. Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Author

Casadei-Gardini, Andrea, primary, Rimini, Margherita, additional, Kudo, Masatoshi, additional, Shimose, Shigeo, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Goh, Myung Ji, additional, Jefremow, Andre, additional, Scartozzi, Mario, additional, Cabibbo, Giuseppe, additional, Campani, Claudia, additional, Tamburini, Emiliano, additional, Tovoli, Francesco, additional, Ueshima, Kazuomi, additional, Aoki, Tomoko, additional, Iwamoto, Hideki, additional, Torimura, Takuji, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, Toyoda, Hidenori, additional, Sakamoto, Naoya, additional, Sho, Takuya, additional, Kang, Wonseok, additional, Siebler, Jürgen, additional, Neurath, Markus Friedrich, additional, Burgio, Valentina, additional, and Cascinu, Stefano, additional

Published
2022
Full Text
View/download PDF

35. Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment

Author

Ueshima, Kazuomi, primary, Komemushi, Atsushi, additional, Aramaki, Takeshi, additional, Iwamoto, Hideki, additional, Obi, Shuntaro, additional, Sato, Yozo, additional, Tanaka, Toshihiro, additional, Matsueda, Kiyoshi, additional, Moriguchi, Michihisa, additional, Saito, Hiroya, additional, Sone, Miyuki, additional, Yamagami, Takuji, additional, Inaba, Yoshitaka, additional, Kudo, Masatoshi, additional, and Arai, Yasuaki, additional

Published
2022
Full Text
View/download PDF

37. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

Author

Kudo, Masatoshi, primary, Montal, Robert, additional, Finn, Richard S., additional, Castet, Florian, additional, Ueshima, Kazuomi, additional, Nishida, Naoshi, additional, Haber, Philipp K., additional, Hu, Youyou, additional, Chiba, Yasutaka, additional, Schwartz, Myron, additional, Meyer, Tim, additional, Lencioni, Riccardo, additional, and Llovet, Josep M., additional

Published
2021
Full Text
View/download PDF

38. Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version)

Author

Kudo, Masatoshi, primary, Ikeda, Masafumi, additional, Ueshima, Kazuomi, additional, Sakamoto, Michiie, additional, Shiina, Shuichiro, additional, Tateishi, Ryosuke, additional, Nouso, Kazuhiro, additional, Hasegawa, Kiyoshi, additional, Furuse, Junji, additional, Miyayama, Shiro, additional, Murakami, Takamichi, additional, Yamashita, Tatsuya, additional, and Kokudo, Norihiro, additional

Published
2021
Full Text
View/download PDF

39. Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease

Author

Hagiwara, Satoru, primary, Nishida, Naoshi, additional, Ueshima, Kazuomi, additional, Minami, Yasunori, additional, Komeda, Yoriaki, additional, Aoki, Tomoko, additional, Takita, Masahiro, additional, Morita, Masahiro, additional, Chishina, Hirokazu, additional, Yoshida, Akihiro, additional, Ida, Hiroshi, additional, and Kudo, Masatoshi, additional

Published
2021
Full Text
View/download PDF

40. Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

Author

Sakai, Kazuko, primary, Sakurai, Toshiharu, additional, De Velasco, Marco A., additional, Nagai, Tomoyuki, additional, Chikugo, Takaaki, additional, Ueshima, Kazuomi, additional, Kura, Yurie, additional, Takahama, Takayuki, additional, Hayashi, Hidetoshi, additional, Nakagawa, Kazuhiko, additional, Kudo, Masatoshi, additional, and Nishio, Kazuto, additional

Published
2021
Full Text
View/download PDF

42. The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function.

Author

Iwamoto, Hideki, Niizeki, Takashi, Nagamatsu, Hiroaki, Ueshima, Kazuomi, Tani, Joji, Kuzuya, Teiji, Kasai, Kazuhiro, Kooka, Youhei, Hiraoka, Atsushi, Sugimoto, Rie, Yonezawa, Takehiro, Tanaka, Satoshi, Deguchi, Akihiro, Shimose, Shigeo, Shirono, Tomotake, Sakai, Miwa, Suzuki, Hiroyuki, Moriyama, Etsuko, Koga, Hironori, and Torimura, Takuji

Subjects
LIVER physiology, HEPATIC artery, DRUG efficacy, CANCER chemotherapy, MULTIVARIATE analysis, MULTIPLE regression analysis, ANTINEOPLASTIC agents, RETROSPECTIVE studies, CANCER patients, SORAFENIB, DESCRIPTIVE statistics, KAPLAN-Meier estimator, SURVIVAL analysis (Biometry), DATA analysis software, STATISTICAL models, HEPATOCELLULAR carcinoma, INTRA-arterial infusions, LONGITUDINAL method, PROPORTIONAL hazards models
Abstract

Simple Summary: New-FP is a regimen of hepatic arterial infusion chemotherapy for hepatocellular carcinoma (HCC). In the study, the regimen significantly prolonged the survival of patients with major portal vein tumor thrombus-HCC. Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal vein tumor thrombus (PVTT). We compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) regimens New-FP and sorafenib for various tumor conditions in preserved liver function. Methods: We retrospectively collected the data of 1709 patients with HCC who were treated with New-FP or sorafenib. Survival was assessed after propensity score matching. Subgroup analyses were conducted: cohort 1 (no MVI or extrahepatic spread (EHS)), cohort 2 (MVI only), cohort 3 (EHS only), cohort 4 (MVI and EHS), and cohort 5 (major PVTT). Results: The New-FP group had a longer median survival time (MST) than the sorafenib in the whole analysis (18 vs. 9 months; p < 0.0001). New-FP demonstrated a longer MST compared with sorafenib in cohort 2 and cohort 4. In cohort 5, the MST of the New-FP group was 16 months, while that of sorafenib was 6 months (p < 0.0001). For major PVTT-HCC, the response rate of New-FP was 73.0%. The MST of patients who achieved complete response with New-FP was 59 months. Conclusions: HAIC using New-FP is promising for patients with MVI- and major PVTT-HCC in preserved liver function. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.

Author

Kudo, Masatoshi, Ueshima, Kazuomi, Ikeda, Masafumi, Torimura, Takuji, Tanabe, Nobukazu, Aikata, Hiroshi, Izumi, Namiki, Yamasaki, Takahiro, Nojiri, Shunsuke, Hino, Keisuke, Tsumura, Hidetaka, Kuzuya, Teiji, Isoda, Norio, Moriguchi, Michihisa, Aino, Hajime, Ido, Akio, Kawabe, Naoto, Nakao, Kazuhiko, Wada, Yoshiyuki, and Ogasawara, Sadahisa

Subjects
CHEMOEMBOLIZATION, HEPATOCELLULAR carcinoma, SORAFENIB, LIVER cancer, PROGRESSION-free survival, DISEASE progression
Abstract

Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). Methods: Patients with unresectable HCC were randomized to a TACE plus sorafenib group (N = 80) or a TACE alone group (N = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. Results: At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607–1.223; p = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466–0.938; p = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (p = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. Conclusions: In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

Author

Kudo, Masatoshi, primary, Ueshima, Kazuomi, additional, Nakahira, Shin, additional, Nishida, Naoshi, additional, Ida, Hiroshi, additional, Minami, Yasunori, additional, Nakai, Takuya, additional, Wada, Hiroshi, additional, Kubo, Shoji, additional, Ohkawa, Kazuyoshi, additional, Morishita, Asahiro, additional, Nomi, Takeo, additional, Ishida, Koji, additional, Kobayashi, Shogo, additional, Umeda, Makoto, additional, Tsurusaki, Masakatsu, additional, Chiba, Yasutaka, additional, Yoshimura, Kenichi, additional, Sakai, Kazuko, additional, and Nishio, Kazuto, additional

Published
2021
Full Text
View/download PDF

47. REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.

Author

Ueshima, Kazuomi, primary, Kudo, Masatoshi, additional, Yamanaka, Takeharu, additional, Aikata, Hiroshi, additional, Yamashita, Tatsuya, additional, Ikeda, Masafumi, additional, Tateishi, Ryosuke, additional, Moriguchi, Michihisa, additional, Hiraoka, Atsushi, additional, Tsuchiya, Kaoru, additional, Ogasawara, Sadahisa, additional, Mochida, Satoshi, additional, Miyayama, Shiro, additional, Hasegawa, Kiyoshi, additional, Yoshimura, Kenichi, additional, and Takehara, Tetsuo, additional

Published
2021
Full Text
View/download PDF

49. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT

Author

Inoue, Tatsuo, Kudo, Masatoshi, Komuta, Mina, Hayaishi, Sosuke, Ueda, Taisuke, Takita, Masahiro, Kitai, Satoshi, Hatanaka, Kinuyo, Yada, Norihisa, Hagiwara, Satoru, Chung, Hobyung, Sakurai, Toshiharu, Ueshima, Kazuomi, Sakamoto, Michiie, Maenishi, Osamu, Hyodo, Tomoko, Okada, Masahiro, Kumano, Seishi, and Murakami, Takamichi

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results